Immune expression profile identification in a group of proliferative verrucous leukoplakia patients: a pre-cancer niche for oral squamous cell carcinoma development


Por: Llorens C, Soriano B, Trilla-Fuertes L, Bagan L, Ramos-Ruiz R, Gamez-Pozo A, Pena C, Bagan J

Publicada: 1 sep 2020 Ahead of Print: 1 sep 2020
Resumen:
Objectives To explore the pathophysiology of proliferative verrucous leukoplakia, a rare oral disorder that exhibits high rates of recurrence and malignant transformation, through a RNAseq case-control study. Material and methods We obtained oral biopsies from 10 patients with verrucous leukoplakia lesions and from the mucosa of 5 healthy individuals for sequencing using RNAseq technology. Using bioinformatic methods, we investigated gene expression and enrichment differences between patients both with and without the disorder. We applied network biology methods to investigate functional relations among those genes that were differentially deregulated. Results We detected 140 differentially expressed genes with distinct roles in immune surveillance, tissue and organ morphogenesis, development, and organization. Of these 140 genes, 111 have been previously described as cancer expression biomarkers, being oral squamous cell carcinoma the most represented type of cancer among them. Of these 140 genes, 26 were prioritized for further investigation as biomarkers using larger sample sizes. Conclusions The gene expression patterns of healthy and unhealthy patients differed in 140 genes whose deregulation has a functional impact on normal functioning of the immune system. This immune expression profile provides a plausible hypothesis to explain the transformation to oral squamous cell carcinoma observed in 6 of the 10 assayed cases.

Filiaciones:
Llorens C:
 Univ Valencia, Biotechvana, Parc Cient, Valencia, Spain

Soriano B:
 Univ Valencia, Biotechvana, Parc Cient, Valencia, Spain

Trilla-Fuertes L:
 Biomed Mol Med SL, Madrid, Spain

Bagan L:
 Univ Valencia, Univ Gen Hosp, Med Oral Unit, Valencia, Spain

Ramos-Ruiz R:
 Parque Cient Madrid, Genom Unit Cantoblanco, Madrid, Spain

Gamez-Pozo A:
 Hosp Univ La Paz IdiPAZ, Mol Oncol & Pathol Lab, Madrid, Spain

Pena C:
 CIBERONC, Inst Ramon y Cajal Invest Sanitaria IRYCIS, Med Oncol Dept, Madrid, Spain

 Inst Ramon y Cajal Invest Sanitaria IRYCIS, Lab Invest Oncol Med, Planta 2 Dcha,Carretera Colmenar,Km 9,100, Madrid 28034, Spain

Bagan J:
 Univ Valencia, Univ Gen Hosp, Med Oral Unit, Valencia, Spain

 Med Bucal Univ Valencia, Hosp Gen Univ Valencia, Serv Estomatol CMF, Fdn Invest, Valencia, Spain
ISSN: 14326981





Clinical Oral Investigations
Editorial
SPRINGER HEIDELBERG, TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY, Alemania
Tipo de documento: Article
Volumen: 25 Número: 5
Páginas: 2645-2657
WOS Id: 000568787300003
ID de PubMed: 32918120

MÉTRICAS